When the data shows that Black women are reporting more symptoms, for longer, and getting less treatment — that's not a mystery to be solved, it's a failure to be named. If your doctor has minimized what you're describing, this research is worth printing out and bringing to your next appointment. You are not exaggerating.
Learn more about Rose →SWAN data consistently showed that Black women experienced hot flashes at higher frequencies than white, Chinese, or Japanese women in the cohort — a finding that held up across multiple study waves. The difference was not marginal: Black women were substantially more likely to report hot flashes as a current symptom at every stage of the menopausal transition. This makes the relatively lower rate of hormone therapy prescribing in this population particularly striking and worth examining.
A landmark analysis of SWAN data published in JAMA Internal Medicine found that the median total duration of frequent vasomotor symptoms was 7.4 years overall, but for Black women the median duration extended to more than 10 years. Symptom duration was measured from first report through the final menstrual period and beyond, meaning many Black women are living with disruptive hot flashes well into postmenopause. This extended burden compounds the downstream effects on sleep, mood, cardiovascular health, and quality of life.
The SWAN data showed that Black women tended to report the onset of vasomotor symptoms earlier in the menopausal transition compared to white women — sometimes while still in the early perimenopause phase with relatively normal cycle regularity. Earlier onset combined with longer duration means the total window of symptom burden is considerably wider. This earlier start point is clinically important because it means symptoms may not be recognized as menopause-related when they first appear, leading to delayed support.
SWAN sleep studies, including data collected with wrist actigraphy, documented that Black women had objectively worse sleep continuity — meaning more fragmented sleep and longer periods of wakefulness after sleep onset — compared to white women. Subjective reports aligned with the objective data: Black women in the cohort were more likely to report difficulty staying asleep and non-restorative sleep across the transition. Because hot flashes and sleep disruption are tightly linked, the higher vasomotor burden in this group likely compounds the sleep problem significantly.
SWAN data confirmed what gynecologists have long observed: Black women have substantially higher rates of uterine fibroids, with estimates suggesting they are two to three times more likely to develop them than white women. Fibroids can cause heavy bleeding, pelvic pain, and anemia during the perimenopause years, layering additional symptoms on top of the standard hormonal transition. This overlap makes it harder to parse what is menopause-related and what is fibroid-related, and it increases the risk that hormonal symptoms get attributed solely to fibroids and vice versa.
Across multiple SWAN study waves, Black women reported higher levels of depressive symptoms than white women during perimenopause, even after researchers controlled for socioeconomic factors, stress, and health status. The relationship between hormonal fluctuation and mood is well established physiologically, but chronic stress — including the documented physiological impact of racial discrimination — is understood to interact with the hypothalamic-pituitary-adrenal axis in ways that may amplify mood vulnerability during hormonal transitions. This is not a simple story of demographics; it reflects how lived experience shapes biology.
SWAN cardiovascular data showed that Black women entered the menopausal transition with higher baseline levels of hypertension and experienced steeper increases in blood pressure across the transition compared to white women. Estrogen loss is associated with unfavorable shifts in lipid profiles and vascular function in all women, but these changes land on a different baseline for many Black women — one already shaped by chronic stress, healthcare access disparities, and higher rates of pre-existing hypertension. The intersection of menopause and cardiovascular risk is therefore more acute and more urgent in this population.
SWAN researchers and subsequent analysts have noted a consistent and troubling gap: despite reporting more severe and more frequent symptoms, Black women in the study were less likely to receive hormone therapy or other evidence-based menopause treatments. This disparity persists even when controlling for health insurance status, suggesting that implicit bias in clinical encounters and historical medical mistrust — shaped by documented abuses in medical research — both play meaningful roles. Undertreated vasomotor symptoms are not a minor inconvenience; they are associated with worse sleep, lower quality of life, and potentially higher cardiovascular risk over time.
The weathering hypothesis, developed by public health researcher Arline Geronimus, proposes that the chronic stress of navigating racism in America leads to accelerated biological aging in Black women — measurable through markers like telomere length and allostatic load. SWAN and related research have found evidence consistent with this in reproductive aging patterns, including earlier menopause onset in some analyses and differences in hormonal trajectories. This means the menopause transition for many Black women may be occurring in a body that has been under sustained physiological stress, which has real implications for how symptoms present, how severe they are, and what the appropriate clinical response should be.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.